Guardant Health GH Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| Biopharma and data | $217.73M+17.5% | $210.13M+18.3% | $205.64M+26.8% | $197.46M+31.9% | $185.37M+32.5% | |
| Licensing and other | $8.85M-13.2% | $8.56M-36.5% | $8.95M-46.9% | $9.73M-51.5% | $10.19M-55.6% | |
| Oncology | $737.99M+30.0% | $683.6M+25.9% | $639.26M+28.3% | $596.05M+30.2% | $567.64M+32.4% | |
| Screening | $115.65M+971% | $79.73M+1,456% | $48.72M+4,758% | $25.62M— | $10.8M— | |
| Revenue by Geography | ||||||
| International | $65.92M+62.5% | $58.74M+40.3% | $51.24M+16.3% | $46.86M+17.2% | $40.57M+4.7% | |
| United States | $1.01B+38.3% | $923.28M+32.4% | $851.33M+31.3% | $781.99M+29.5% | $733.42M+29.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Guardant Health break its business down?
- Guardant Health (GH) reports total revenue by product across 4 parts — Biopharma and data, Licensing and other, Oncology and Screening. Each is extracted from the segment footnotes and tracked over time.
- Where does Guardant Health's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Guardant Health's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
